System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Ming-Huang Chen is an expert in Oncology at Taipei Veterans General Hospital (Taiwan). As of October 2026, ScienceLeadR ranks Ming-Huang Chen in the top 1% of experts worldwide for Biliary Tract Neoplasms, Biliary Tract Diseases and Carcinoma. Ming-Huang Chen has authored 249 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 9 of them ongoing. SLR score: 1,200 (community average: 125). How the SLR is computed.

LeadR Profile

Ming-Huang Chen Taipei Veterans General Hospital Taiwan
1 200 ScienceLeadR Reputation 1200

Unlock

Register Login
Network Map

Oncology

Subspecialties: Hepatology - Pharmacy - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026
Source: PubMed

Taipei Veterans General Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 249

Citations

Citations: 5 822 1st author: 28 Last author: 24 Unique author: 3

Main journals

J Clin Oncol 18
J Chin Med Assoc 15
Oncotarget 13
Journal of Cancer Research and Practice 11
Oncologist 7

Best Journals

J Clin Oncol 12
N Engl J Med 3
Ann Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Selection and Management of Patients With Resectable Gastric or Gastroesophageal Junction Cancer Receiving Perioperative FLOT: A Modified Delphi Consensus Approach.
PMID 42900867 — esophagogastric junction, neoplasms, fluorouracil		JCO Oncol Pract20260
Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial.
PMID 42898854 — biliary tract neoplasms, safety, neoplasms, biliary tract, therapeutics		EClinicalMedicine20260
Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
PMID 42716074 — leucovorin, disease-free survival, docetaxel, adenocarcinoma, oxaliplatin, fluorouracil, therapeutics		Lancet Top journal20262
Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.
PMID 42393461 — safety, neoplasms, neuroendocrine tumors, therapeutics		Br J Cancer20261
Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors.
PMID 42371780 — pancreatic neoplasms, safety, pharmaceutical preparations, neoplasms, therapeutics, colorectal neoplasms, pharmacokinetics		Oncologist20260

Clinical Studies 25

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6 Study Chair: 2 Study Director: 2 Sub-Investigator: 1

By phase:

Phase 2 15
Phase 3 5
Phase 1 2
N/A 1
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 8
Active not recruiting 6
Recruiting 5
Terminated 2
Unknown 2
Not yet recruiting 1
Withdrawn 1

By type:

Interventional 24
Observational 1

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 4
multicentric5to9 6
multicentricup10 8

Main Topics

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
DURATION GC FLOT Plus Durvalumab and TS 1 Plus Durvalumab for Resectable Gastric Cancer
NCT07757191 — safety, neoplasms, drug therapy, neoadjuvant therapy, therapeutics, stomach neoplasms, chemotherapy		Phase 2Not yet recruiting2026
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
NCT07039162 — radiotherapy, cells, paclitaxel, carcinoma, squamous cell, neoplasms, disease progression, chemoradiotherapy, esophageal squamous cell carcinoma, therapeutics, esophageal neoplasms, carcinoma		Phase 2Recruiting2025
A Study of CHS 114 (Tagmokitug) in Combination With Toripalimab and or Other Treatments in Participants With Advanced Solid Tumors
NCT06657144 — cells, stomach, safety, esophagus, carcinoma, squamous cell, neoplasms, adenocarcinoma, fluorouracil, solutions, aminocaproates, neoplasm metastasis, esophageal squamous cell carcinoma, therapeutics, colorectal neoplasms, stomach neoplasms, carcinoma		Phase 1Recruiting2025
Safety and Tolerability Study for T 1301 Capsules to Treat Advanced Solid Tumors
NCT05156203 — administration, oral, safety, pharmaceutical preparations, lymphoma, neoplasms, multiple chronic conditions, capsules, gelatin, therapeutics, pharmacokinetics		Phase 1Recruiting2021
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2 positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147 — cells, lewy bodies, stomach, parkinson disease, esophagus, neoplasms, adenocarcinoma, drug therapy, oxaliplatin, fluorouracil, immunotherapy, receptors, death domain, esophageal neoplasms, capecitabine, cell death, stomach neoplasms, trastuzumab, chemotherapy		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS